InterCure H1 Revenue NIS125.733M Down From NIS208.614M YoY, Adjusted EBITDA NIS20.829M Down From NIS29.669M YoY
Revenues for the first half of 2024 were affected by damages caused by the terrorist attack on October 7, 2023, and the war in Gaza.
InterCure is entitled to full compensation from the Israeli authorities for all
